Driven largely by opioid litigation against the pharmaceutical industry, class action settlements rose to unprecedented levels in 2022, a new report published by the law firm Duane Morris found.

Class actions and government enforcement lawsuits against opioid manufactures, retailers and distributors rang up more than $50 billion in settlements last year, according to the Duane Morris Class Action Review, which draws conclusions from the hundreds of rulings in the last year.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]